HC Wainwright Issues Optimistic Outlook for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for TScan Therapeutics in a research report issued on Tuesday, September 8th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.08) per share for the quarter, up from their prior forecast of ($0.22). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at ($0.24) EPS.

A number of other research analysts have also issued reports on TCRX. Wedbush lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a report on Wednesday, September 2nd. Lifesci Capital cut TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Weiss Ratings lowered shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Benchmark reiterated a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $2.67.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $0.33 on Thursday. TScan Therapeutics has a 52 week low of $0.33 and a 52 week high of $2.57. The company has a fifty day simple moving average of $0.79 and a two-hundred day simple moving average of $0.97. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. The company has a market cap of $22.37 million, a price-to-earnings ratio of -0.36 and a beta of 1.07.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%.

Institutional Trading of TScan Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Panagora Asset Management Inc. acquired a new stake in shares of TScan Therapeutics in the 4th quarter valued at about $25,000. Landscape Capital Management L.L.C. purchased a new stake in TScan Therapeutics in the second quarter valued at approximately $25,000. HRT Financial LP acquired a new stake in shares of TScan Therapeutics in the fourth quarter valued at approximately $26,000. Public Employees Retirement System of Ohio acquired a new stake in shares of TScan Therapeutics in the first quarter valued at approximately $28,000. Finally, Boothbay Fund Management LLC grew its position in shares of TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.